化学生物学作为一种神经调节方法，用于治疗神经精神疾病和障碍。

Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.

机构信息

National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA; Department of Neuroscience, Johns Hopkins University, Baltimore, MD 21218, USA.

Harvard Medical School, Boston, MA 02115, USA.

出版信息

Mol Ther. 2022 Mar 2;30(3):990-1005. doi: 10.1016/j.ymthe.2021.11.019. Epub 2021 Dec 1.

DOI:10.1016/j.ymthe.2021.11.019

PMID:34861415

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8899595/

Abstract

Chemogenetics enables precise, non-invasive, and reversible modulation of neural activity via the activation of engineered receptors that are pharmacologically selective to endogenous or exogenous ligands. With recent advances in therapeutic gene delivery, chemogenetics is poised to support novel interventions against neuropsychiatric diseases and disorders. To evaluate its translational potential, we performed a scoping review of applications of chemogenetics that led to the reversal of molecular and behavioral deficits in studies relevant to neuropsychiatric diseases and disorders. In this review, we present these findings and discuss the potential and challenges for using chemogenetics as a precision medicine-based neuromodulation strategy.

摘要

化学生物学通过激活工程受体来实现对神经活动的精确、非侵入性和可逆调节，这些受体对内源性或外源性配体具有药理学选择性。随着治疗性基因传递的最新进展，化学生物学有望为神经精神疾病和障碍提供新的干预措施。为了评估其转化潜力，我们对化学生物学的应用进行了范围界定综述，这些应用导致了与神经精神疾病和障碍相关研究中分子和行为缺陷的逆转。在本综述中，我们介绍了这些发现，并讨论了化学生物学作为一种基于精准医学的神经调节策略的潜力和挑战。